These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 21747756)

  • 21. Extracellular α-synuclein--a possible initiator of inflammation in Parkinson's disease.
    Ren WQ; Tian ZM; Yin F; Sun JZ; Zhang JN
    Pharmazie; 2016 Feb; 71(2):51-5. PubMed ID: 27004367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TLR4 deficiency has a protective effect in the MPTP/probenecid mouse model of Parkinson's disease.
    Shao QH; Chen Y; Li FF; Wang S; Zhang XL; Yuan YH; Chen NH
    Acta Pharmacol Sin; 2019 Dec; 40(12):1503-1512. PubMed ID: 31388087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of MyD88-dependent TLR1/2 signaling by misfolded α-synuclein, a protein linked to neurodegenerative disorders.
    Daniele SG; Béraud D; Davenport C; Cheng K; Yin H; Maguire-Zeiss KA
    Sci Signal; 2015 May; 8(376):ra45. PubMed ID: 25969543
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cx3cr1-deficiency exacerbates alpha-synuclein-A53T induced neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease.
    Castro-Sánchez S; García-Yagüe ÁJ; López-Royo T; Casarejos M; Lanciego JL; Lastres-Becker I
    Glia; 2018 Aug; 66(8):1752-1762. PubMed ID: 29624735
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alpha-Synuclein Proteins Promote Pro-Inflammatory Cascades in Microglia: Stronger Effects of the A53T Mutant.
    Hoenen C; Gustin A; Birck C; Kirchmeyer M; Beaume N; Felten P; Grandbarbe L; Heuschling P; Heurtaux T
    PLoS One; 2016; 11(9):e0162717. PubMed ID: 27622765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of Galectin-3 in α-synuclein-induced microglial activation.
    Boza-Serrano A; Reyes JF; Rey NL; Leffler H; Bousset L; Nilsson U; Brundin P; Venero JL; Burguillos MA; Deierborg T
    Acta Neuropathol Commun; 2014 Nov; 2():156. PubMed ID: 25387690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson's disease.
    Drouin-Ouellet J; St-Amour I; Saint-Pierre M; Lamontagne-Proulx J; Kriz J; Barker RA; Cicchetti F
    Int J Neuropsychopharmacol; 2014 Dec; 18(6):. PubMed ID: 25522431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synuclein activates microglia in a model of Parkinson's disease.
    Su X; Maguire-Zeiss KA; Giuliano R; Prifti L; Venkatesh K; Federoff HJ
    Neurobiol Aging; 2008 Nov; 29(11):1690-701. PubMed ID: 17537546
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lycopodium Attenuates Loss of Dopaminergic Neurons by Suppressing Oxidative Stress and Neuroinflammation in a Rat Model of Parkinson's Disease.
    Jayaraj RL; Beiram R; Azimullah S; Meeran MFN; Ojha SK; Adem A; Jalal FY
    Molecules; 2019 Jun; 24(11):. PubMed ID: 31185705
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microglia in dementia with Lewy bodies.
    Streit WJ; Xue QS
    Brain Behav Immun; 2016 Jul; 55():191-201. PubMed ID: 26518296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
    Schulz-Schaeffer WJ
    Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition.
    Croisier E; Moran LB; Dexter DT; Pearce RK; Graeber MB
    J Neuroinflammation; 2005 Jun; 2():14. PubMed ID: 15935098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-cell-autonomous Neurotoxicity of α-synuclein Through Microglial Toll-like Receptor 2.
    Kim C; Lee HJ; Masliah E; Lee SJ
    Exp Neurobiol; 2016 Jun; 25(3):113-9. PubMed ID: 27358579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathomechanism Characterization and Potential Therapeutics Identification for Parkinson's Disease Targeting Neuroinflammation.
    Chen CM; Yen CY; Chen WL; Lin CH; Wu YR; Chang KH; Lee-Chen GJ
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33494411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia.
    Fellner L; Irschick R; Schanda K; Reindl M; Klimaschewski L; Poewe W; Wenning GK; Stefanova N
    Glia; 2013 Mar; 61(3):349-60. PubMed ID: 23108585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Misfolded α-synuclein and Toll-like receptors: therapeutic targets for Parkinson's disease.
    Béraud D; Maguire-Zeiss KA
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1(0 1):S17-20. PubMed ID: 22166424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipid-mediated oxidative stress and inflammation in the pathogenesis of Parkinson's disease.
    Farooqui T; Farooqui AA
    Parkinsons Dis; 2011 Feb; 2011():247467. PubMed ID: 21403820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration.
    Gao HM; Kotzbauer PT; Uryu K; Leight S; Trojanowski JQ; Lee VM
    J Neurosci; 2008 Jul; 28(30):7687-98. PubMed ID: 18650345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.